Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

By M. Tanner, Maija Hollmén, T. Junttila, A. Kapanen, S. Tommola, Y. Soini, H. Helin, J. Salo, Heikki Joensuu, E. Sihvo and 2 more. Annals of Oncology, 2005

743 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/8da0fdbab08981435c80d7f50d731cc06edc0484

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Radiology, Nuclear Medicine and Imaging

Citations in the corpus

Assessment of a HER2 scoring system for gastric cancer: results from a validation study (2008, background): “The rate of HER2 positivity in gastric cancer is estimated to be between 15% and 20%.(8,19) However, to our knowledge there has been no validation or standardization of HER2 testing in gastric cancer to date.”
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. (2008, background): “mutations are typical for diffuse gastric and lobular invasive breast carcinomas, but rare in intestinal gastric and ductal invasive breast carcinomas [39].”
Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer (2014, background): “Preclinical studies have indicated that trastuzumab can impede HER2-overexpressing human gastric cancer cells growth and inhibit tumorigenesis in xenograft models [34-36].”
Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications (2014, positive): “Other studies also confirmed a higher rate of HER2 positivity in GEJ tumors and intestinal subtype [31, 32].”
Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. (2009, neutral): “3, 11), and 20% to 24% of gastric cancers (5, 12).”